Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- CaseBioscience® schließt sich einem Team an, das von ARPA-H bis zu 7,3 Millionen US-Dollar für die Weiterentwicklung der Lagerung von Zelltherapien bei Raumtemperatur erhältFORT COLLINS, Colorado, 3. Oktober 2026 -- CaseBioscience® gab heute seine Beteiligung an einem multidisziplinären Team unter der Leitung von Likarda bekannt, dem von der Advanced Research Projects Agency for Health (ARPA-H) im Rahmen ihres Programms „BioStabilization...
- Antengene Corporation LimitedAntengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Resonant Clinical Solutions développe ses activités mondiales dans le domaine des équipements et accessoires médicaux grâce à l'acquisition de LabfishCette acquisition renforce la présence de Resonant en Europe et lui apporte une expertise spécialisée en étalonnage, une couverture IOR/EOR, ainsi que des dépôts partenaires pour accompagner le cycle de vie des essais cliniques à l'échelle mondiale LEESBURG, Virginie, 3 octobre 2026...
- Resonant Clinical Solutions amplía su negocio global de equipos y accesorios con la adquisición de LabfishLa adquisición amplía la presencia de Resonant en Europa e incorpora experiencia especializada en calibración, alcance en IOR/EOR y centros asociados para respaldar el ciclo de vida de los ensayos clínicos a escala mundial LEESBURG, Va., 3 de octubre de 2026 -- Resonant...
- Little River Memorial Hospital Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is ExposedEdelson Lechtzin LLP, a class action law firm, is investigating data privacy claims arising from a reported data breach at Little River Memorial Hospital
- Grammy-Winning Bassist Stanley Clarke Reflects on Losing Friends to Drugs and the Mentor Who Changed His LifeStanley Clarke recalls how jazz legend Chick Corea helped him step away from drugs and introduced him to Dianetics: The Modern Science of Mental Health.
- Novo provides update on the denecimig Biologics License Application (BLA) in the USCompanies: Novo NordiskBagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
- ORIC PharmaceuticalsORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.
- Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on October 1, 2026, and ending at the close of business on December 31, 2026. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted. Any determination regarding the convertibility of the Notes during future periods will be made in accordance with the terms of the Indenture governing the Notes.
- Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed’s board of directors granted 19 new non-executive employees non-qualified stock options to purchase an aggregate of 481,300 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $22.54, which is equal to Apnimed’s closing trading price on the grant date. One-fourth of the shares underlying each of the employee’s stock options will vest on the first anniversary of each employee’s start date and in equal monthly installments thereafter for the next three years, subject to such employee’s continued employment with the Company on such vesting dates.